DRL launches nitroglycerin sublingual tablets in US

HYDERABAD: Dr Reddy's Laboratories today said it has launched nitroglycerin sublingual tablets, a therapeutic equivalent generic version of Nitrostat (Nitroglycerin) sublingual tablets in the US.

The drug which is used in preventing or relieving a sudden attack of angina (chest pain) caused by heart disease was approved by the United States Food and Drug Administration ( USFDA).

According to a statement issued by the drug maker, Nitrostat (Nitroglycerin) sublingual tablet brand had the US sales of about USD 108 million for the most recent 12 months ending in March 2016 (according to IMS Health data).

Dr Reddy's Nitroglycerin sublingual tablets USP, 0.4 mg is available in bottle count size of 100 and a bundle of 4 bottles of count size 25, Nitroglycerin sublingual tablets USP, 0.3 mg is available in bottle count size of 100 and the Nitroglycerin sublingual tablets USP, 0.6 mg is available in bottle count size of 100, it added.

DRL shares are trading at Rs 3,049.90 on BSE in afternoon session.